BridgeBio Pharma, Inc. (BBIO)Healthcare | Biotechnology | Palo Alto, United States | NasdaqGS
83.08 USD
-2.81
(-3.272%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:19 a.m. EDT
BridgeBio is currently riding a powerful wave of momentum, having surged nearly 25 percent in just two weeks as the market digests positive clinical developments and analyst upgrades. The consensus among professionals is strongly bullish, with a target price implying nearly 20 percent upside from current levels. However, this enthusiasm masks significant financial fragility. While revenue growth is explosive at 67 percent and gross margins are industry-leading, the company is burning through cash with negative free flow and a balance sheet weighed down by substantial debt. The valuation is stretched, with a forward price-to-earnings ratio exceeding 150 times, pricing in perfection that hasn't yet been delivered. For investors, this is a high-risk, high-reward speculative play dependent on the success of its drug pipeline rather than a stable income generator. The recent price action suggests smart money is positioning for a catalyst, but the lack of dividends and ongoing cash burn means the thesis relies entirely on future execution. |
| Model | MAE |
|---|---|
| MSTL_84 ✓ | 0.105007 |
| AutoARIMA | 0.107165 |
| AutoTheta | 0.110176 |
| AutoETS | 0.110193 |
| MSTL | 0.123594 |
| MSTL_84_105 | 0.141161 |
| MSTL_105 | 0.165024 |
Forecast horizon: 60 days | Selected: MSTL_84
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 1.00 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 3.46 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 3.01 |
| Market Cap | 16,272,152,576 |
| Forward P/E | 146.08 |
| Beta | 0.95 |
| Profit Margins | -124.42% |
| Website | https://bridgebio.com |
As of July 11, 2026, 6:19 a.m. EDT: Implied volatility remains elevated across all expirations, indicating heightened uncertainty and anticipation of catalysts. Call volume is concentrated near the current price and slightly out-of-the-money strikes (75 to 87.5), while put volume is heavy at lower strikes (60 to 75). This mixed positioning suggests speculators are hedging against downside risk while maintaining exposure to potential upside from upcoming trial results or partnerships.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.7689769 |
| Address1 | 3,160 Porter Drive |
| Address2 | Suite 250 |
| All Time High | 93.415 |
| All Time Low | 4.98 |
| Ask | 88.89 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 5,084,610 |
| Average Daily Volume3 Month | 3,642,019 |
| Average Volume | 3,642,019 |
| Average Volume10Days | 5,084,610 |
| Beta | 0.954 |
| Bid | 77.44 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | -11.642 |
| City | Palo Alto |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 83.08 |
| Current Ratio | 1.521 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 85.38 |
| Day Low | 81.39 |
| Display Name | BridgeBio Pharma |
| Earnings Call Timestamp End | 1,778,185,800 |
| Earnings Call Timestamp Start | 1,778,185,800 |
| Earnings Timestamp | 1,778,184,000 |
| Earnings Timestamp End | 1,785,873,600 |
| Earnings Timestamp Start | 1,785,873,600 |
| Ebitda | -498,881,984 |
| Ebitda Margins | -0.8602 |
| Enterprise To Ebitda | -35.747 |
| Enterprise To Revenue | 30.75 |
| Enterprise Value | 17,833,670,656 |
| Eps Current Year | -2.15623 |
| Eps Forward | 0.56872 |
| Eps Trailing Twelve Months | -3.74 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 69.9231 |
| Fifty Day Average Change | 13.1568985 |
| Fifty Day Average Change Percent | 0.18816239 |
| Fifty Two Week Change Percent | 76.89769 |
| Fifty Two Week High | 93.415 |
| Fifty Two Week High Change | -10.334999 |
| Fifty Two Week High Change Percent | -0.110635325 |
| Fifty Two Week Low | 42.09 |
| Fifty Two Week Low Change | 40.99 |
| Fifty Two Week Low Change Percent | 0.97386557 |
| Fifty Two Week Range | 42.09 - 93.415 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,561,642,200,000 |
| Float Shares | 164,674,256 |
| Forward Eps | 0.56872 |
| Forward P E | 146.08244 |
| Free Cashflow | -317,910,112 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 834 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.95127 |
| Gross Profits | 551,696,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03921 |
| Held Percent Institutions | 1.03154 |
| Implied Shares Outstanding | 195,861,242 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California. |
| Long Name | BridgeBio Pharma, Inc. |
| Market | us_market |
| Market Cap | 16,272,152,576 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_412911458 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -721,552,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 16,272,151,985 |
| Number Of Analyst Opinions | 22 |
| Open | 85.38 |
| Operating Cashflow | -443,953,984 |
| Operating Margins | -0.54472 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 650 391 9740 |
| Pre Market Change | 0.36450195 |
| Pre Market Change Percent | 0.43873608 |
| Pre Market Price | 83.4445 |
| Pre Market Time | 1,784,028,515 |
| Previous Close | 85.89 |
| Price Eps Current Year | -38.530212 |
| Price Hint | 2 |
| Price To Book | -7.136231 |
| Price To Sales Trailing12 Months | 28.057467 |
| Profit Margins | -1.24415 |
| Quick Ratio | 1.403 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.43478 |
| Region | US |
| Regular Market Change | -2.81 |
| Regular Market Change Percent | -3.27162 |
| Regular Market Day High | 85.38 |
| Regular Market Day Low | 81.39 |
| Regular Market Day Range | 81.39 - 85.38 |
| Regular Market Open | 85.38 |
| Regular Market Previous Close | 85.89 |
| Regular Market Price | 83.08 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 3,263,045 |
| Return On Assets | -0.2798 |
| Revenue Growth | 0.668 |
| Revenue Per Share | 3.01 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 195,861,242 |
| Shares Percent Shares Out | 0.123100005 |
| Shares Short | 24,102,938 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 24,391,359 |
| Short Name | BridgeBio Pharma, Inc. |
| Short Percent Of Float | 0.1374 |
| Short Ratio | 5.83 |
| Source Interval | 15 |
| State | CA |
| Symbol | BBIO |
| Target High Price | 157.0 |
| Target Low Price | 80.0 |
| Target Mean Price | 104.69955 |
| Target Median Price | 100.5 |
| Total Cash | 940,185,984 |
| Total Cash Per Share | 4.8 |
| Total Debt | 2,492,216,064 |
| Total Revenue | 579,958,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.74 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 69.3177 |
| Two Hundred Day Average Change | 13.762299 |
| Two Hundred Day Average Change Percent | 0.19853945 |
| Type Disp | Equity |
| Volume | 3,263,045 |
| Website | https://bridgebio.com |
| Zip | 94,304 |